At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 413 enrolled
Drug / intervention
botulinum toxin neuromodulator +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
In Brief
A Phase 3 clinical trial evaluating botulinum toxin neuromodulator and Placebo for Glabellar Frown Lines (GL) and Lateral Canthal Lines (LCL). Completed, enrolled 413 participants across 12 sites in 2 countries.
Detailed Summary
This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartFeb 2020
Primary CompletionOct 2020
Study CompletionFeb 2021
TodayJul 2026
First PostedJan 29, 2020
Enrollment StartFeb 10, 2020
Primary CompletionOct 2, 2020
Study CompletionFeb 26, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.4 years ago
Interventions
botulinum toxin neuromodulatorbiological
QM1114-DP will be injected into either the LCL, GL, or both the LCL and GL
Placebobiological
Placebo will be injected into either the LCL, GL, or both the LCL and GL